Cocrystal Pharma, Inc. 8-K

What Happened
Cocrystal Pharma, Inc. (COCP) filed an 8-K on February 19, 2026, issuing a press release that its first oral norovirus protease inhibitor, CDI-988, will be featured at the International Society for Antiviral Research (ISAR/ICAR) Conference 2026. The conference runs April 27–May 1, 2026, in Prague, Czech Republic.

Key Details

• Press release and Regulation FD disclosure filed on February 19, 2026.
• CDI-988 identified as the company’s first oral norovirus protease inhibitor.
• CDI-988 will be featured at ICAR (ISAR) 2026 in Prague, Apr 27–May 1, 2026.
• The press release was furnished as Exhibit 99.1 in the 8-K filing.

Why It Matters
This 8-K is a Regulation FD disclosure making the market aware of Cocrystal’s public presentation plans for CDI-988. For investors, a feature at a major antiviral research conference can increase scientific visibility and provide an opportunity for the company to share data or development updates with the research community and potential partners. The filing itself does not include clinical or financial results, but it flags an upcoming milestone and public engagement around the company’s norovirus program.